Who is sponsoring NCT05372692?

NCT05372692 is sponsored by Weijia Fang, MD.

What drugs are being tested in NCT05372692?

Interventions in NCT05372692: mesothelin-specific chimeric antigen receptor T cell injection.

What condition does NCT05372692 study?

NCT05372692 studies Ovarian Cancer.

Is NCT05372692 still recruiting?

NCT05372692 is currently completed. Last updated 17 July 2023.

Last reviewed 2023-07-17 · How we verify

NCT05372692

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

Completed NA Last updated 17 July 2023

What this trial tests

NA trial testing mesothelin-specific chimeric antigen receptor T cell injection in Ovarian Cancer in 3 participants. Completed in 1 February 2023.

Timeline

12 April 2022

Primary endpoint
1 February 2023

1 February 2023

Quick facts

Lead sponsor	Weijia Fang, MD
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	sequential
Masking	none
Primary purpose	treatment
Enrollment	3
Start date	12 April 2022
Primary completion	1 February 2023
Estimated completion	1 February 2023
Sites	1 location across China

Drugs / interventions tested

mesothelin-specific chimeric antigen receptor T cell injection — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Weijia Fang, MD — full company profile →

Who can join

18 and older, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Early-stage Clinical Study of mesothelin-specific Chimericantigen Receptor T Cells (LD013) in Subjects With Refractory or Relapsed mesothelin-positive Ovarian Cancer

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Advances and obstacles of T cell-based immunotherapy in gynecological malignancies.
Zhao X, Ran J, Li S, Chen J. · · 2025 · cited 14× · PMID 40713697 · DOI 10.1186/s12943-025-02411-w
Understanding CAR T cell therapy and its role in ovarian cancer and peritoneal carcinomatosis from ovarian cancer.
Domínguez-Prieto V, Qian S, Villarejo-Campos P, Meliga C, et al · · 2023 · cited 14× · PMID 37274261 · DOI 10.3389/fonc.2023.1104547
CAR Based Immunotherapy of Solid Tumours-A Clinically Based Review of Target Antigens.
Maher J, Davies DM. · · 2023 · cited 13× · PMID 36829563 · DOI 10.3390/biology12020287
Single CAR-T cell treatment controls disseminated ovarian cancer in a syngeneic mouse model.
Ranoa DRE, Sharma P, Schane CP, Lewis AN, et al · · 2023 · cited 12× · PMID 37258040 · DOI 10.1136/jitc-2022-006509
Recent advances in understanding the immune microenvironment in ovarian cancer.
Chen J, Yang L, Ma Y, Zhang Y. · · 2024 · cited 11× · PMID 38903506 · DOI 10.3389/fimmu.2024.1412328
Application of CAR-T cell therapy targeting mesothelin in solid tumor treatment.
Chen Q, Sun Y, Li H. · · 2024 · cited 10× · PMID 39023820 · DOI 10.1007/s12672-024-01159-x
The Landscape of Adoptive Cellular Therapies in Ovarian Cancer.
Davis L, Miller RE, Wong YNS. · · 2023 · cited 10× · PMID 37835509 · DOI 10.3390/cancers15194814
Decoding the role of mesothelin in tumor dynamics and targeted treatment innovations.
Silvestri R, Colucci E, Piccardi M, Landi S, et al · · 2025 · cited 2× · PMID 41335396 · DOI 10.1186/s43556-025-00379-z

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Weijia Fang, MD trials

Trials by the same sponsor.

NCT07420010 — An Open-label, Single-arm Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary · EARLY_PHASE1 · not yet recruiting
NCT06821048 — Study of CEA Targeting CAR-T (PTC13) in the Treatment of CEA-Positive Advanced Malignant Solid Tumors · Phase 1 · recruiting
NCT05862168 — Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single- · Phase 2 · recruiting
NCT05947201 — Neoadjuvant Treatment of Cadonilimab Combined Albumin-paclitaxel, Cisplatin and Fluorouracil for Resectable Locally Adva · Phase 2 · unknown
NCT05518253 — A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors · Phase 1 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05372692 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Weijia Fang, MD
Last refreshed: 17 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05372692.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing